A minimum CR2 binding domain of C3d enhances immunity following vaccination.

A minimum CR2 binding domain of C3d enhances immunity following vaccination. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A minimum CR2 binding domain of C3d enhances immunity following vaccination. Abstract Text:

Joseph F Bower,Ted M Ross,

The degradation product of the third (C3) complement component, C3d, links innate and adaptive immunity, and the covalent attachment of C3d to an antigen enhances antigen-specific immune responses. C3d has been hypothesized to enhance immunity by direct interaction with complement receptor 2 (CR2/CD21) on immune cells. However, the domains on C3d important for CR2 binding have been controversial, with various studies reaching contradictory conclusions. In addition, the concept of B-cell activation via CR2 by C3d has been questioned, since mice lacking CR2 still elicit C3d-enhanced immunity following vaccination. Therefore, the goal of this study was to determine if a peptide representing one of the proposed CR2 binding domains of C3d could substitute for the entire protein and enhance antigen-specific immunity. Mice (BALB/c) were vaccinated with the HIV-1 gp120 envelope glycoprotein (Env(gp120)) alone or fused to multiple copies of the murine C3d or a twenty-eight amino-acid peptide (P28) containing a minimum CR2 binding domain. Each immunogen was expressed from DNA plasmid in vivo or injected as purified recombinant protein. The fusion of the P28 peptide to Env(gp120) enhanced both humoral and cell-mediated immune responses with similar efficiency as Env(gp120) conjugated to C3d. The fusion of C3d or P28 to Env(gp120) elicited higher-titer anti-Env specific antibody, enhanced avidity maturation of the elicited antibody, and elicited higher numbers of IFN-gamma and IL-4 secreting cells compared to Env(gp120) immunizations. This CR2-binding domain specific 28 amino acid peptide can substitute for the entire C3d molecule and enhance immunity. These results indicate that the adjuvant properties of C3d are associated with CR2 interaction.

A minimum CR2 binding domain of C3d enhances immunity following vaccination. Publishing Authors By Initials

JF Bower,TM Ross,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A minimum CR2 binding domain of C3d enhances immunity following vaccination. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Advances in experimental medicine and biology

VOLUME: 586

Page Numbers: 249-64

Journal Abbreviation:

ISSN: 0065-2598

DAY: 3

MONTH: 12

YEAR: 2006

A minimum CR2 binding domain of C3d enhances immunity following vaccination. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 121103

A minimum CR2 binding domain of C3d enhances immunity following vaccination. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A minimum CR2 binding domain of C3d enhances immunity following vaccination. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A minimum CR2 binding domain of C3d enhances immunity following vaccination.

AFFILIATION: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, School of Medicine, Pittsburgh, PA, 15261, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Adv Exp Med Biol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A minimum CR2 binding domain of C3d enhances immunity following vaccination Related Publications

• A minimum CR2 binding domain of C3d enhances immunity following vaccination.
• Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children.
• Benjamin M. Baker, JR.: 1901-2003.
• Birth characteristics, maternal reproductive history, and the risk of infant leukemia: a report from the Children's Oncology Group.
• Carnitine as a possible adjunct in parenteral feeding.
• Chronic vitamin A status and acute repletion with retinyl palmitate are determinants of the distribution and catabolism of all-trans-retinoic acid in rats.
• Circadian rhythms play role in cancer research.
• Complement inactivating proteins and intraspecies venom variation in Crotalus oreganus helleri.
• Differences in cyclin D2 and D1 protein expression distinguish forebrain progenitor subsets.
• Diffusion imaging: insight to cell status and cytoarchitecture.
• Failure of embryos from bluetongue infected cattle to transmit virus to susceptible recipients or their offspring.
• Gestational programming of offspring obesity/hypertension.
• Kinetics of glial glutamine efflux and the mechanism of neuronal uptake studied in vivo in mildly hyperammonemic rat brain.
• Language use in females with fragile X or Turner syndrome during brief initial social interactions.
• Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.
• Maternal hemoglobin concentration during pregnancy and risk of infant leukaemia: a children's oncology group study.
• More to the E-Ferol case than presented.
• Neurologic Manifestations
  of HIV Infection Without AIDS:Follow-UP of a Cohort
  of Homosexual and Bisexual Men.
• Penicillin; applied pharmacology.
• Phosphorylation-regulated inhibition of the Gz GTPase-activating protein activity of RGS proteins by synapsin I.
• Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.
• Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.
• Random activation energy model and disordered kinetics, from static to dynamic disorder.
• Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope.
• Species differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential oxidative and hydrolytic metabolism by humans and rats.
• The effect of lactation length on the circulating concentrations of progesterone and oestradiol in the early weaned sow.
• Transoral surgery: an anatomic study.
• Use of modified pericranial flaps in anterior skull base reconstruction: technical note.
• Vascular targeted nanoparticles for imaging and treatment of brain tumors.
• Virus-like particles: designing an effective AIDS vaccine.